This was a retrospective study assessing the clinical activity, outcomes, and potential clinical factors associated with survival among patients with BRAFV600-mutated metastatic melanoma treated with BRAF/MEKi after disease progression on immune checkpoint inhibition. The gene discussed is BRAF; the disease is metastatic melanoma.